Business Context and Reporting Period
Company: IMPACT BIOMEDICAL INC.
Filing Type: Form 8-K (Current Report)
Date of Report: April 3, 2025
Reporting Period: Events occurring on or before April 3, 2025, specifically regarding a transaction dated March 24, 2025.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. The only financial data disclosed relates to a specific debt instrument:
- Debt Instrument: Amended and Restated Promissory Note with DSS, Inc.
- Original Principal: $12,000,000
- Principal Balance (as of March 24, 2025): $13,176,477.03
- Equity Issuance: No shares were issued in connection with the agreement.
Material Changes
The filing reports a material change regarding a previously announced Debt Conversion Agreement:
- Agreement Status: The Company entered into a Debt Conversion Agreement on March 24, 2025, to convert the Promissory Note into equity.
- Withdrawal: DSS, Inc. has withdrawn from the Debt Conversion Agreement due to current market conditions.
- Outcome: The conversion did not proceed, and no shares were issued. The debt obligation remains outstanding.
Guidance, Outlook, and Risks
Management Commentary: The Company attributes the withdrawal of the debt conversion to "current market conditions."
Risks and Contingencies: The failure to convert the debt implies the Company must continue servicing the $13.18 million principal balance in cash or through other means, rather than reducing debt via equity issuance. The filing does not provide specific forward-looking guidance or updated risk factors beyond this event.
Investor Verification Checklist
- Verify the current status of the $13,176,477.03 Promissory Note and whether interest continues to accrue.
- Confirm if the Company has alternative financing plans to address the debt given the failed conversion.
- Review the March 28, 2025 Initial 8-K for the original terms of the proposed conversion.
- Assess the impact of "current market conditions" on the Company's ability to secure future financing or equity transactions.